Sokal Adam, Lenarczyk Radoslaw, Kowalski Oskar, Mitrega Katarzyna, Pluta Slawomir, Stabryla-Deska Joanna, Streb Witold, Urbanik Zofia, Krzeminski Tadeusz F, Kalarus Zbigniew
Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Centre for Heart Diseases.
Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Centre for Heart Diseases.
Heart Rhythm. 2016 May;13(5):1088-1095. doi: 10.1016/j.hrthm.2015.12.036. Epub 2016 Jan 8.
A substantial proportion of patients do not respond to cardiac resynchronization therapy (CRT). Various echocardiographic and biochemical markers including collagen turnover biomarkers were suggested to predict CRT results. However, pathological significance of collagen turnover biomarkers in CRT remains controversial.
The aim of the present study was to evaluate the relationship between levels of collagen turnover biomarkers (amino-terminal propeptide of procollagen type I and amino-terminal propeptide of procollagen type III [PIIINP]), N-terminal of the prohormone brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein, and matrix metalloproteinases (metalloproteinase-2 and metalloproteinase-9) and echocardiographic response to CRT and clinical outcomes.
The study population consisted of patients enrolled in the Triple Site Versus Standard Cardiac Resynchronization Therapy trial. Blood samples were obtained before implantation of a CRT with defibrillator. The levels of PIIINP, amino-terminal propeptide of procollagen type I, metalloproteinase-2, and metalloproteinase-9 were determined using commercially available ELISA kits. High-sensitivity C-reactive protein and NT-proBNP levels were determined in a standard way.
Samples were collected from 74 of 100 enrolled patients. The multivariate logistic regression analysis demonstrated that low PIIINP levels (odds ratio [OR] 3.56; 95% confidence interval [CI] 1.23-10.24; P = .017) and baseline ejection fraction (OR 2.14; 95% CI 1.11-4.11; P = .02) were favorably associated with echocardiographic response. PIIINP and NT-proBNP levels appeared to be independent predictors of all-cause mortality (PIIINP: OR 3.11; 95% CI 1.21-7.89; P = .033; NT-proBNP: OR 2.05; 95% CI 1.11-4.96; P = .039) and risk of major cardiac adverse event (PIIINP: OR 3.56; 95% CI 1.53-9.15; P = .007; NT-proBNP: OR 4.51; 95% CI 1.75-11.6; P = .001). PIIINP levels showed significant additive value in predicting mortality as compared with NT-proBNP levels, but they were not superior to ejection fraction in predicting response. Survival analysis with cutoff values identified by receiver operating characteristic analysis confirmed a significant benefit associated with low baseline PIIINP levels.
Low PIIINP levels are associated with favorable echocardiographic response and long-term survival in CRT recipients.
相当一部分患者对心脏再同步治疗(CRT)无反应。包括胶原转换生物标志物在内的各种超声心动图和生化标志物被认为可预测CRT效果。然而,胶原转换生物标志物在CRT中的病理意义仍存在争议。
本研究旨在评估胶原转换生物标志物(I型前胶原氨基端前肽和III型前胶原氨基端前肽[PIIINP])、脑钠肽原N端(NT-proBNP)、高敏C反应蛋白和基质金属蛋白酶(金属蛋白酶-2和金属蛋白酶-9)水平与CRT的超声心动图反应及临床结局之间的关系。
研究人群包括参与三部位与标准心脏再同步治疗试验的患者。在植入带除颤器的CRT之前采集血样。使用市售ELISA试剂盒测定PIIINP、I型前胶原氨基端前肽、金属蛋白酶-2和金属蛋白酶-9的水平。以标准方法测定高敏C反应蛋白和NT-proBNP水平。
从100名登记患者中的74名采集了样本。多因素逻辑回归分析表明,低PIIINP水平(比值比[OR]3.56;95%置信区间[CI]1.23 - 10.24;P = 0.017)和基线射血分数(OR 2.14;95% CI 1.11 - 4.11;P = 0.02)与超声心动图反应呈正相关。PIIINP和NT-proBNP水平似乎是全因死亡率(PIIINP:OR 3.11;95% CI 1.21 - 7.89;P = 0.033;NT-proBNP:OR 2.05;95% CI 1.11 - 4.96;P = 0.039)和主要心脏不良事件风险(PIIINP:OR 3.56;95% CI 1.53 - 9.15;P = 0.007;NT-proBNP:OR 4.51;95% CI 1.75 - 11.6;P = 0.001)的独立预测因素。与NT-proBNP水平相比,PIIINP水平在预测死亡率方面显示出显著的附加价值,但在预测反应方面并不优于射血分数。通过受试者工作特征分析确定临界值的生存分析证实,低基线PIIINP水平具有显著益处。
低PIIINP水平与CRT接受者良好的超声心动图反应和长期生存相关。